{"id":3096,"date":"2026-05-29T03:01:33","date_gmt":"2026-05-29T10:01:33","guid":{"rendered":"https:\/\/xpharma.com.cn\/?p=3096"},"modified":"2026-05-29T03:01:33","modified_gmt":"2026-05-29T10:01:33","slug":"yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome","status":"publish","type":"post","link":"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\/","title":{"rendered":"Yangtze River Pharmaceutical Group (YRPG): ZGZHR-061 Granules approved for clinical trial targeting asthma with Cold Wheezing Syndrome"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Currently, Class 1.1 innovative TCM drugs for bronchial asthma chronic persistent phase (Cold Wheezing Syndrome) remain scarce.YRPG&#8217;s ZGZHR-061 Granules target this condition, fitting respiratory chronic disease needs.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The drug first filed for a clinical trial on March 13, 2026, and received approval on May 25, 2026.ZGZHR-061 Granules (Class 1.1 TCM) warm Yang, supplement Qi, unblock lung, and stop wheezing.It also relieves cough and phlegm for bronchial asthma chronic persistent phase (Cold Wheezing Syndrome).Respiratory TCM drugs are a mainstream golden track in the pharma market, with huge volume and rigid long-term demand.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In 2025, total hospital sales of respiratory TCM drugs in China exceeded 50 billion RMB.In TCM innovation, YRPG has formed a tiered R&amp;D structure.To date, YRPG has four Class 1.1 TCM drugs approved for clinical trials.They are ZGZHR-061 Granules, ZYY-742 Gel, Qingchang Wenzhong Tablets, and Qinqiao Yanshu Granules.These drugs cover multiple therapeutic areas, with continuous original R&amp;D achievements from YRPG.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Currently, Class 1.1 innovative TCM drugs for bronchial asthma chronic persistent phase (Cold Wheezing Syndrome) remain scarce.YRPG&#8217;s ZGZHR-061 Granules target this condition, fitting respiratory chronic disease needs. The drug first filed for a clinical trial on March 13, 2026, and received approval on May 25, 2026.ZGZHR-061 Granules (Class 1.1 TCM) warm Yang, supplement Qi, unblock [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":3090,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[17],"tags":[],"class_list":["post-3096","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drug-development"],"blocksy_meta":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Yangtze River Pharmaceutical Group (YRPG): ZGZHR-061 Granules approved for clinical trial targeting asthma with Cold Wheezing Syndrome - Xpharma China<\/title>\n<meta name=\"description\" content=\"Yangtze River Pharmaceutical Group (YRPG): ZGZHR-061 Granules approved for clinical trial targeting asthma with Cold Wheezing Syndrome - Xpharma China\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Yangtze River Pharmaceutical Group (YRPG): ZGZHR-061 Granules approved for clinical trial targeting asthma with Cold Wheezing Syndrome - Xpharma China\" \/>\n<meta property=\"og:description\" content=\"Yangtze River Pharmaceutical Group (YRPG): ZGZHR-061 Granules approved for clinical trial targeting asthma with Cold Wheezing Syndrome - Xpharma China\" \/>\n<meta property=\"og:url\" content=\"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\/\" \/>\n<meta property=\"og:site_name\" content=\"Xpharma China\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/61590027634719\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-29T10:01:33+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/Yangtze-River-Pharmaceutical-Group.png\" \/>\n\t<meta property=\"og:image:width\" content=\"420\" \/>\n\t<meta property=\"og:image:height\" content=\"310\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"xpharmanews\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Xpharma007\" \/>\n<meta name=\"twitter:site\" content=\"@Xpharma007\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"xpharmanews\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/2026\\\/05\\\/29\\\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/2026\\\/05\\\/29\\\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\\\/\"},\"author\":{\"name\":\"xpharmanews\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/person\\\/c292b26c0a3311036ce0f5ab28a1ea05\"},\"headline\":\"Yangtze River Pharmaceutical Group (YRPG): ZGZHR-061 Granules approved for clinical trial targeting asthma with Cold Wheezing Syndrome\",\"datePublished\":\"2026-05-29T10:01:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/2026\\\/05\\\/29\\\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\\\/\"},\"wordCount\":171,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/2026\\\/05\\\/29\\\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Yangtze-River-Pharmaceutical-Group.png\",\"articleSection\":[\"Drug development\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/2026\\\/05\\\/29\\\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\\\/#respond\"]}]},{\"@type\":[\"WebPage\",\"MedicalWebPage\"],\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/2026\\\/05\\\/29\\\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\\\/\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/2026\\\/05\\\/29\\\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\\\/\",\"name\":\"Yangtze River Pharmaceutical Group (YRPG): ZGZHR-061 Granules approved for clinical trial targeting asthma with Cold Wheezing Syndrome - Xpharma China\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/2026\\\/05\\\/29\\\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/2026\\\/05\\\/29\\\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Yangtze-River-Pharmaceutical-Group.png\",\"datePublished\":\"2026-05-29T10:01:33+00:00\",\"description\":\"Yangtze River Pharmaceutical Group (YRPG): ZGZHR-061 Granules approved for clinical trial targeting asthma with Cold Wheezing Syndrome - Xpharma China\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/2026\\\/05\\\/29\\\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/2026\\\/05\\\/29\\\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/2026\\\/05\\\/29\\\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\\\/#primaryimage\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Yangtze-River-Pharmaceutical-Group.png\",\"contentUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Yangtze-River-Pharmaceutical-Group.png\",\"width\":420,\"height\":310},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/2026\\\/05\\\/29\\\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9875\",\"item\":\"https:\\\/\\\/xpharma.com.cn\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Yangtze River Pharmaceutical Group (YRPG): ZGZHR-061 Granules approved for clinical trial targeting asthma with Cold Wheezing Syndrome\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#website\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/\",\"name\":\"Xpharma China - International Pharmaceutical wholesaler and retailer\",\"description\":\"Xpharma China\",\"publisher\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/xpharma.com.cn\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\",\"name\":\"Xpharma China\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/logo.gif\",\"contentUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/logo.gif\",\"width\":679,\"height\":166,\"caption\":\"Xpharma China\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/61590027634719\\\/\",\"https:\\\/\\\/x.com\\\/Xpharma007\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/person\\\/c292b26c0a3311036ce0f5ab28a1ea05\",\"name\":\"xpharmanews\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"caption\":\"xpharmanews\"},\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/author\\\/xpharmanews\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Yangtze River Pharmaceutical Group (YRPG): ZGZHR-061 Granules approved for clinical trial targeting asthma with Cold Wheezing Syndrome - Xpharma China","description":"Yangtze River Pharmaceutical Group (YRPG): ZGZHR-061 Granules approved for clinical trial targeting asthma with Cold Wheezing Syndrome - Xpharma China","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\/","og_locale":"en_US","og_type":"article","og_title":"Yangtze River Pharmaceutical Group (YRPG): ZGZHR-061 Granules approved for clinical trial targeting asthma with Cold Wheezing Syndrome - Xpharma China","og_description":"Yangtze River Pharmaceutical Group (YRPG): ZGZHR-061 Granules approved for clinical trial targeting asthma with Cold Wheezing Syndrome - Xpharma China","og_url":"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\/","og_site_name":"Xpharma China","article_publisher":"https:\/\/www.facebook.com\/61590027634719\/","article_published_time":"2026-05-29T10:01:33+00:00","og_image":[{"width":420,"height":310,"url":"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/Yangtze-River-Pharmaceutical-Group.png","type":"image\/png"}],"author":"xpharmanews","twitter_card":"summary_large_image","twitter_creator":"@Xpharma007","twitter_site":"@Xpharma007","twitter_misc":{"Written by":"xpharmanews","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\/#article","isPartOf":{"@id":"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\/"},"author":{"name":"xpharmanews","@id":"https:\/\/xpharma.com.cn\/#\/schema\/person\/c292b26c0a3311036ce0f5ab28a1ea05"},"headline":"Yangtze River Pharmaceutical Group (YRPG): ZGZHR-061 Granules approved for clinical trial targeting asthma with Cold Wheezing Syndrome","datePublished":"2026-05-29T10:01:33+00:00","mainEntityOfPage":{"@id":"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\/"},"wordCount":171,"commentCount":0,"publisher":{"@id":"https:\/\/xpharma.com.cn\/#organization"},"image":{"@id":"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\/#primaryimage"},"thumbnailUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/Yangtze-River-Pharmaceutical-Group.png","articleSection":["Drug development"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\/#respond"]}]},{"@type":["WebPage","MedicalWebPage"],"@id":"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\/","url":"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\/","name":"Yangtze River Pharmaceutical Group (YRPG): ZGZHR-061 Granules approved for clinical trial targeting asthma with Cold Wheezing Syndrome - Xpharma China","isPartOf":{"@id":"https:\/\/xpharma.com.cn\/#website"},"primaryImageOfPage":{"@id":"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\/#primaryimage"},"image":{"@id":"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\/#primaryimage"},"thumbnailUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/Yangtze-River-Pharmaceutical-Group.png","datePublished":"2026-05-29T10:01:33+00:00","description":"Yangtze River Pharmaceutical Group (YRPG): ZGZHR-061 Granules approved for clinical trial targeting asthma with Cold Wheezing Syndrome - Xpharma China","breadcrumb":{"@id":"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\/#primaryimage","url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/Yangtze-River-Pharmaceutical-Group.png","contentUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/Yangtze-River-Pharmaceutical-Group.png","width":420,"height":310},{"@type":"BreadcrumbList","@id":"https:\/\/xpharma.com.cn\/index.php\/2026\/05\/29\/yangtze-river-pharmaceutical-group-yrpg-zgzhr-061-granules-approved-for-clinical-trial-targeting-asthma-with-cold-wheezing-syndrome\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9875","item":"https:\/\/xpharma.com.cn\/"},{"@type":"ListItem","position":2,"name":"Yangtze River Pharmaceutical Group (YRPG): ZGZHR-061 Granules approved for clinical trial targeting asthma with Cold Wheezing Syndrome"}]},{"@type":"WebSite","@id":"https:\/\/xpharma.com.cn\/#website","url":"https:\/\/xpharma.com.cn\/","name":"Xpharma China - International Pharmaceutical wholesaler and retailer","description":"Xpharma China","publisher":{"@id":"https:\/\/xpharma.com.cn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/xpharma.com.cn\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/xpharma.com.cn\/#organization","name":"Xpharma China","url":"https:\/\/xpharma.com.cn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/xpharma.com.cn\/#\/schema\/logo\/image\/","url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/logo.gif","contentUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/logo.gif","width":679,"height":166,"caption":"Xpharma China"},"image":{"@id":"https:\/\/xpharma.com.cn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/61590027634719\/","https:\/\/x.com\/Xpharma007"]},{"@type":"Person","@id":"https:\/\/xpharma.com.cn\/#\/schema\/person\/c292b26c0a3311036ce0f5ab28a1ea05","name":"xpharmanews","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","caption":"xpharmanews"},"url":"https:\/\/xpharma.com.cn\/index.php\/author\/xpharmanews\/"}]}},"_links":{"self":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3096","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/comments?post=3096"}],"version-history":[{"count":1,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3096\/revisions"}],"predecessor-version":[{"id":3102,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3096\/revisions\/3102"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/media\/3090"}],"wp:attachment":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/media?parent=3096"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/categories?post=3096"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/tags?post=3096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}